

## Proxy Voting Record

### Next Edge Biotech and Life Sciences Opportunities Fund

For the period of July 1, 2020 to June 30, 2021



Next Edge Capital Corp.

1 Toronto St. Suite 200

Toronto, ON M5C 2V6

Tel: 416-775-3600

[www.nextedgecapital.com](http://www.nextedgecapital.com)

## Proxy Voting Record

Proxy Voting Report: Q3 2020

Next Edge Biotech and Life Sciences Opportunities Fund

For the period of July 1, 2020 to September 30, 2020

\* Fund was launched December 18<sup>th</sup>, 2020 \*

## Proxy Voting Record

Proxy Voting Report: Q4 2020

Next Edge Biotech and Life Sciences Opportunities Fund

For the period of October 1, 2020 to December 31, 2020

\* Fund was launched December 18<sup>th</sup> 2020 \*

\* No proxies were voted for this period \*

## Proxy Voting Record

Proxy Voting Report: Q1 2021

Next Edge Biotech and Life Sciences Opportunities Fund

For the period of January 1, 2021 to March 31, 2021

## Proxy Voting Record

### MICROBIX BIOSYSTEMS INC.

Ticker Symbol:	MBXBF	Meeting Type	Annual and Special Meeting
CUSIP:	59501P104	Meeting Date	March 30, 2021

Item	Proposal	Vote	For/Against Management
1.	Election of Directors		
	1. Peter M. Blecher	For	For
	2. Mark A Cochran	For	For
	3. V. C. Embro-Pantalony	For	For
	4. Anthony Giovinazzo	For	For
	5. Joseph D. Renner	For	For
	6. Martin Marino	For	For
	7. Cameron Groome	For	For
2.	Appointment of Ernst & Young LLP as Auditors of the Company.	For	For
3.	An ordinary resolution re-approving the Company's Stock Option Plan.	For	For
4.	An ordinary resolution approving the amendment of the term of Warrants held by Insiders of the Company.	For	For

# Proxy Voting Record

## SQI DIAGNOSTICS INC.

Ticker Symbol:	SQIDF	Meeting Type	Annual and Special Meeting
CUSIP:	78466B108	Meeting Date	March 31, 2021

Item	Proposal	Vote	For/Against Management
1.	Election of Directors		
	1. Clive Beddoe	For	For
	2. Gerald R. Connor	For	For
	3. Wilmot Matthews	For	For
	4. Andrew Morris	For	For
	5. Claude Ricks	For	For
	6. Robert Chioini	For	For
	7. Eric Brouwer	For	For
	8. Eric Zwisler	For	For
2.	Appointment of RSM Canada LLP as Auditors of the Company for the ensuing year and authorizing the Directors to fix their remuneration.	For	For
3.	To consider, and if thought advisable, approve, with or without amendment, an ordinary resolution of disinterested shareholders of the Company to ratify, confirm and approve the adoption of the amended and restated stock option plan of the Company, as previously approved by the board of directors of the Company, as more fully described in the accompanying management information circular furnished at the Meeting.	For	For
4.	Subject to the approval of the Stock Option Plan Resolution, above, to consider, and if thought advisable, pass with or without amendment, an ordinary resolution of disinterested shareholders of the Company to ratify, confirm and approve the grant of certain stock options to the Chief Executive Officer of the Company, Mr. Robert Chioini, exercisable into an aggregate of up to 29,835,062 common shares under the amended and restated stock option plan of the Company, as	For	For

## Proxy Voting Record

previously approved by the board of directors of the Company, and as more fully described in the accompanying management information circular furnished at the Meeting.

- |    |  |     |     |
|----|--|-----|-----|
| 5. | To approve a special resolution authorizing an amendment to the articles of the Company (the full text of which is included in the accompanying management Information Circular) to consolidate the issued and outstanding common shares in the capital of the Company at the ratio of between five and ten pre-consolidation common shares for everyone post-consolidation common share, as and when determined by the board of directors of the Company. | For | For |
|----|--|-----|-----|

## Proxy Voting Record

Proxy Voting Report: Q2 2021

Next Edge Biotech and Life Sciences Opportunities Fun

For the period of April 1, 2021 to June 30, 2021



## Proxy Voting Record

### SYNAPTOGENIX INC

Ticker Symbol:	SNPX	Meeting Type	Special
CUSIP:	87167T102	Meeting Date	April 07, 2021

Item	Proposal	Vote	For/Against Management
1.	Proposal to approve a proposed amendment to the Synaptogenix, Inc. Amended and Restated Certificate of Incorporation to effect a reverse stock split of our issued and outstanding shares of common stock, at a ratio of between 1-for-1.5 and 1-for-20.	For	For
2.	Proposal to approve a proposed amendment to the Synaptogenix, Inc. 2020 Equity Incentive Plan to increase the number of shares available for the grant of awards by 1,500,000 shares.	For	For
3.	Proposal to approve one or more adjournments to the Special Meeting, if necessary or appropriate, to permit further solicitation of proxies if there are not sufficient votes at the time of the Special Meeting cast in favor of Proposal No. 1 or Proposal No. 2.	For	For

# Proxy Voting Record

## PROVENTION BIO INC

Ticker Symbol:	PRVB	Meeting Type	Annual
CUSIP:	74374N102	Meeting Date	May 12, 2021

Item	Proposal	Vote	For/Against Management
1.	Election of Directors		
	1. Ashleigh Palmer	For	For
	2. Jeffrey Bluestone	For	For
	3. Avery Catlin	For	For
	4. Sean Doherty	For	For
	5. Wayne Pisano	For	For
	6. Nancy Wysenski	For	For
	7. John Jenkins	For	For
2.	Approval, on a non-binding advisory basis, of the compensation of the Company's named executive officers.	For	For
3.	Approval, on a non-binding advisory basis, of the frequency of future non-binding advisory votes on the compensation of the Company's named executive officers.	For	For
4.	Approval of an amendment to the Company's Second Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 100,000,000 to 150,000,000 shares.	For	For
5.	Ratification of EisnerAmper, LLP as the Company's independent registered public accounting firm for the year ending December 31, 2021.	For	For

## Proxy Voting Record

### THERATECHNOLOGIES INC.

Ticker Symbol:	THTX	Meeting Type	Annual
CUSIP:	88338H100	Meeting Date	May 13, 2021

Item	Proposal	Vote	For/Against Management
1.	Election of Directors		
	1. Joseph Arena	For	For
	2. Gérald A. Lacoste	For	For
	3. Paul Lévesque	For	For
	4. Gary Littlejohn	For	For
	5. Andrew Molson	For	For
	6. Alain Trudeau	For	For
	7. Dawn Svoronos	For	For
	8. Dale MacCandlish Weil	For	For
2.	Appointment of KPMG, LLP as Auditors of the Corporation and authorizing the Directors to fix their remuneration.	For	For

## Proxy Voting Record

### PROQR THERAPEUTICS NV

Ticker Symbol:	PRQR	Meeting Type	Annual
CUSIP:	N71542109	Meeting Date	May 19, 2021

Item	Proposal	Vote	For/Against Management
1.	Adoption of the annual accounts, including the appropriation of net result, for the financial year 2020.	For	For
2.	Release from liability of the members of the Management Board with respect to the performance of their management during the financial year 2020.	For	For
3.	Release from liability of the members of the Supervisory Board with respect to the performance of their supervision during the financial year 2020.	For	For
4.	Re-appointment of Supervisory Board member Antoine Papiernik.	For	For
5.	Appointment of KPMG Accountants N.V. as the Company's external auditor for the financial year 2022.	For	For
6.	First amendment of the Articles of Association of the Company.	For	For
7.	Second amendment of the Articles of Association of the Company.	For	For
8.	Amendment of the Compensation Principles for the Supervisory Board.	For	For
9.	Authorization of the Management Board to issue ordinary shares.	For	For

## Proxy Voting Record

- |     |   |     |     |
|-----|---|-----|-----|
| 10. | Authorization of the Management Board to acquire ordinary shares in the capital of the Company. | For | For |
|-----|---|-----|-----|

## Proxy Voting Record

### SANGAMO THERAPEUTICS, INC.

Ticker Symbol:	SGMO	Meeting Type	Annual
CUSIP:	800677106	Meeting Date	May 25, 2021

Item	Proposal	Vote	For/Against Management
1.1.	Election of Director to serve until the 2022 annual meeting: Robert F. Carey.	For	For
1.2.	Election of Director to serve until the 2022 annual meeting: Kenneth J. Hillan, M.B., Ch.B., Ph.D.	For	For
1.3.	Election of Director to serve until the 2022 annual meeting: Alexander D. Macrae, M.B., Ch.B., Ph.D.	For	For
1.4.	Election of Director to serve until the 2022 annual meeting: John H. Markels, Ph.D.	For	For
1.5.	Election of Director to serve until the 2022 annual meeting: James R. Meyers.	For	For
1.6.	Election of Director to serve until the 2022 annual meeting: H. Stewart Parker.	For	For
1.7.	Election of Director to serve until the 2022 annual meeting: Saira Ramasastry.	For	For
1.8.	A Election of Director to serve until the 2022 annual meeting: Karen L. Smith, M.D., Ph.D., M.B.A., L.L.M.	For	For
1.9.	Election of Director to serve until the 2022 annual meeting: Joseph S. Zakrzewski.	For	For

## Proxy Voting Record

- |    |  |     |     |
|----|--|-----|-----|
| 2. | To approve, on an advisory basis, the compensation of our named executive officers, as described in the accompanying proxy statement.  | For | For |
| 3. | To approve the Sangamo Therapeutics, Inc. 2020 Employee Stock Purchase Plan pursuant to which 5,000,000 shares of our common stock will be available for sale and issuance to our employees. | For | For |
| 4. | To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the year ending December 31, 2021.   | For | For |

## Proxy Voting Record

### INCYTE CORPORATION

Ticker Symbol:	INCY	Meeting Type	Annual
CUSIP:	45337C102	Meeting Date	May 26, 2021

Item	Proposal	Vote	For/Against Management
1.1.	Election of Director: Julian C. Baker.	For	For
1.2.	Election of Director: Jean-Jacques Bienaimé	For	For
1.3.	Election of Director: Paul J. Clancy.	For	For
1.4.	Election of Director: Wendy L. Dixon.	For	For
1.5.	Election of Director: Jacquelyn A. Fouse.	For	For
1.6.	Election of Director: Edmund P. Harrigan	For	For
1.7.	Election of Director: Katherine A. High.	For	For
1.8.	Election of Director: Hervé Hoppenot.	For	For
1.7.	Election of Director to serve until the 2022 annual meeting: Saira Ramasastry.	For	For
1.8.	A Election of Director to serve until the 2022 annual meeting: Karen L. Smith, M.D., Ph.D., M.B.A., L.L.M.	For	For
1.7.	Election of Director: Katherine A. High.	For	For
1.8.	Election of Director: Hervé Hoppenot.	For	For
2.	Approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers.	For	For
3.	Approve amendments to the Company's Amended and Restated 2010 Stock Incentive Plan.	For	For



## Proxy Voting Record

- |    |  |     |     |
|----|--|-----|-----|
| 4. | Ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for 2021. | For | For |
|----|--|-----|-----|

## Proxy Voting Record

### EXELIXIS, INC.

Ticker Symbol:	EXEL	Meeting Type	Annual
CUSIP:	30161Q104	Meeting Date	May 26, 2021

Item	Proposal	Vote	For/Against Management
1A.	Election of Director: Charles Cohen, Ph.D.	For	For
1B.	Election of Director: Carl B. Feldbaum, Esq.	For	For
1C.	Election of Director: Maria C. Freire, Ph.D.	For	For
1D.	Election of Director: Alan M. Garber, M.D., Ph.D.	For	For
1E.	Election of Director: Vincent T. Marchesi, M.D., Ph.D.	For	For
1F.	Election of Director: Michael M. Morrissey, Ph.D.	For	For
1G.	Election of Director: Stelios Papadopoulos, Ph.D.	For	For
1H.	Election of Director: George Poste, DVM, Ph.D., FRS.	For	For
1I.	Election of Director: Julie Anne Smith.	For	For
1J.	Election of Director: Lance Willsey, M.D.	For	For
1K.	Election of Director: Jack L. Wyszomierski.	For	For
2.	To ratify the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as Exelixis' independent registered public accounting firm for the fiscal year ending December 31, 2021.	For	For
3.	To approve, on an advisory basis, the compensation of Exelixis' named executive officers, as disclosed in the accompanying Proxy Statement.	For	For

## Proxy Voting Record

### ATHIRA PHARMA INC.

Ticker Symbol:	ATHA	Meeting Type	Annual
CUSIP:	04746L104	Meeting Date	May 27, 2021

Item	Proposal	Vote	For/Against Management
1.	Election of Directors		
	1. Tadataka Yamada	For	For
	2. Leen Kawas	For	For
	3. Barbara Kosacz	For	For
2.	To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the year ending December 31, 2021.	For	For

## Proxy Voting Record

### INTERCEPT PHARMACEUTICALS, INC.

Ticker Symbol:	ICPT	Meeting Type	Annual
CUSIP:	45845P108	Meeting Date	May 27, 2021

Item	Proposal	Vote	For/Against Management
1A.	Election of Director to serve until the 2022 Annual Meeting: Paolo Fundarò.	For	For
1B.	Election of Director to serve until the 2022 Annual Meeting: Jerome Durso.	For	For
1C.	Election of Director to serve until the 2022 Annual Meeting: Srinivas Akkaraju, M.D., Ph.D.	For	For
1D.	Election of Director to serve until the 2022 Annual Meeting: Luca Benatti, Ph.D.	For	For
1E.	Election of Director to serve until the 2022 Annual Meeting: Daniel Bradbury.	For	For
1F.	Election of Director to serve until the 2022 Annual Meeting: Keith Gottesdiener, M.D.	For	For
1G.	Election of Director to serve until the 2022 Annual Meeting: Nancy Miller-Rich.	For	For
1H.	Election of Director to serve until the 2022 Annual Meeting: Mark Pruzanski, M.D.	For	For
1I.	Election of Director to serve until the 2022 Annual Meeting: Dagmar Rosa-Bjorkeson.	For	For
1J.	Election of Director to serve until the 2022 Annual Meeting: Gino Santini.	For	For
1K.	Election of Director to serve until the 2022 Annual Meeting: Glenn Sblendorio.	For	For
2.	FOR the approval of a one-time stock option exchange program for non-executive employees.	For	For

## Proxy Voting Record

- |    |  |     |     |
|----|--|-----|-----|
| 3. | FOR the approval, on a non-binding, advisory basis, of the compensation of the Company's named executive officers.   | For | For |
| 4. | Voting on a non-binding, advisory basis, that the stockholder advisory vote on the compensation of the Company's named executive officers should occur every ONE YEAR. | For | For |
| 5. | FOR the ratification of the appointment of KPMG LLP as the Company's independent registered public accounting firm for the year ending December 31, 2021.              | For | For |

## Proxy Voting Record

INMUNE BIO INC			
Ticker Symbol:	INMB	Meeting Type	Annual
CUSIP:	45782T105	Meeting Date	June 1, 2021
Item	Proposal	Vote	For/Against Management
1.	Election of Directors		
	1. Edgardo Baracchini, PhD	For	For
	2. J. Kelly Ganjei	For	For
	3. Scott Juda, JD	For	For
	4. Tim Schroeder	For	For
	5. David Szymkowski, PhD	For	For
	6. Raymond J. Tesi, MD	For	For
	7. Marcia Allen	For	For
2.	To ratify the appointment of Marcum LLP as the Company's independent registered public accounting firm for the year ending December 31, 2021.	For	For
3.	To approve the INmune Bio, Inc. 2021 Stock Incentive Plan.	For	For

## Proxy Voting Record

### APELLIS PHARMACEUTICALS INC.

Ticker Symbol:	APLS	Meeting Type	Annual
CUSIP:	03753U106	Meeting Date	June 1, 2021

Item	Proposal	Vote	For/Against Management
1.	Election of Directors		
	1. Paul Fonteyne	For	For
	2. Stephanie M. O'Brien	For	For
2.	To ratify the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2021.	For	For
3.	To approve an advisory vote on executive compensation.	For	For

## Proxy Voting Record

### YUMANITY THERAPEUTICS, INC.

Ticker Symbol:	YMTX	Meeting Type	Annual
CUSIP:	98872L102	Meeting Date	June 02, 2021

Item	Proposal	Vote	For/Against Management
1A.	Election of Class III director to serve until the 2024 Annual Meeting: N. Anthony Coles, M.D.	For	For
1B.	Election of Class III director to serve until the 2024 Annual Meeting: Kim C. Drapkin.	For	For
1C.	Election of Class III director to serve until the 2024 Annual Meeting: Lynne Zydowsky, Ph.D.	For	For
2.	To ratify the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2021.	For	For



## Proxy Voting Record

EDITAS MEDICINE, INC.			
Ticker Symbol:	EDIT	Meeting Type	Annual
CUSIP:	28106W103	Meeting Date	June 3, 2021
Item	Proposal	Vote	For/Against Management
1.	Election of Directors		
	1. Meeta Chatterjee, Ph.D.	For	For
	2. Andrew Hirsch	For	For
2.	To approve, on an advisory basis, the compensation paid to the Company's named executive officers.	For	For
3.	To ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2021.	For	For

## Proxy Voting Record

### AURINIA PHARMACEUTICALS INC.

Ticker Symbol:	AUPH	Meeting Type	Annual and Special Meeting
CUSIP:	05156V102	Meeting Date	June 7, 2021

Item	Proposal	Vote	For/Against Management
1.	To fix the number of directors to be elected at eight (8).	For	For
2.	Election of Directors		
	1. George Milne	For	For
	2. Peter Greenleaf	For	For
	3. David R.W. Jayne	For	For
	4. Joseph P. Hagan	For	For
	5. Daniel Billen	For	For
	6. R. Hector MacKay-Dunn	For	For
	7. Jill Leversage	For	For
	8. Timothy P. Walbert	For	For
3.	Appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm until the close of the 2022 annual general meeting of shareholders or until a successor is appointed. To withhold your vote, mark the against box.	For	For
4.	To approve, on a non-binding advisory basis, a "say on pay" resolution regarding the Company's executive compensation set forth in the Company's Proxy Statement/Circular.	For	For
5.	To approve, on a non-binding advisory basis, the frequency of future advisory votes on "say on pay" as occurring every 1, 2 or 3 years.	For	For
6.	To approve the Company's Amended and Restated Equity Incentive Plan as adopted by the Board as set forth in the Company's Proxy Statement/Circular.	For	For
7.	To approve the 2021 Employee Share Purchase Plan as set forth in the Company's Proxy Statement/Circular.	For	For

## Proxy Voting Record

- |    |   |     |     |
|----|---|-----|-----|
| 8. | To confirm the Company's Amended and Restated By-law No. 2 to increase the quorum for shareholder meetings to 33 1/3% as adopted by the Board as set forth in the Company's Proxy Statement/Circular. | For | For |
|----|---|-----|-----|

## Proxy Voting Record

### AEGLEA BIOTHERAPEUTICS, INC.

Ticker Symbol:	AGLE	Meeting Type	Annual
CUSIP:	00773J103	Meeting Date	June 8, 2021

Item	Proposal	Vote	For/Against Management
1.	Election of Directors		
	1. Russell J. Cox	For	For
	2. I. M. Liebisch Ph.D.	For	For
2.	Ratify the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2021.	For	For

## Proxy Voting Record

### ATARA BIOTHERAPEUTICS, INC.

Ticker Symbol:	ATRA	Meeting Type	Annual
CUSIP:	046513107	Meeting Date	June 8, 2021

Item	Proposal	Vote	For/Against Management
1.	Election of Directors		
	1. Eric L. Dobmeier	For	For
	2. William K. Heiden	For	For
	3. Beth Seidenberg, M.D.	For	For
2.	To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the Proxy Statement.	For	For
3.	To ratify the selection of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2021.	For	For

## Proxy Voting Record

### MEIRAGTX HOLDINGS PLC

Ticker Symbol:	MGTX	Meeting Type	Annual
CUSIP:	G59665102	Meeting Date	June 10, 2021

Item	Proposal	Vote	For/Against Management
1.	Election of Directors		
	1. Alexandria Forbes, Ph.D	For	For
	2. Keith R. Harris, Ph.D.	For	For
	3. Lord Mendoza	For	For
2.	To ratify, by ordinary resolution, the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2021.	For	For

## Proxy Voting Record

### ALKERMES PLC

Ticker Symbol:	ALKS	Meeting Type	Annual
CUSIP:	G01767105	Meeting Date	June 14, 2021

Item	Proposal	Vote	For/Against Management
1.1.	Election of Class I Director: David A. Daglio, Jr.	For	For
1.2.	Election of Class I Director: Nancy L. Snyderman, M.D.	For	For
1.3.	Election of Class I Director: Frank Anders Wilson.	For	For
1.4.	Election of Class I Director: Nancy J. Wysenski.	For	For
2.	To approve, in a non-binding, advisory vote, the compensation of the Company's named executive officers.	For	For
3.	To ratify, in a non-binding vote, the appointment of PricewaterhouseCoopers LLP as the independent auditor and accounting firm of the Company and to authorize, in a binding vote, the Audit and Risk Committee of the Board to set the independent auditor and accounting firm's remuneration.	For	For
4.	To approve the Alkermes plc 2018 Stock Option and Incentive Plan, as amended.	For	For
5.	To approve certain amendments to the Company's Articles of Association that would serve to declassify the Board.	For	For

## Proxy Voting Record

### ALBIREO PHARMA INC.

Ticker Symbol:	ALBO	Meeting Type	Annual
CUSIP:	01345P106	Meeting Date	June 17, 2021

Item	Proposal	Vote	For/Against Management
1.	Election of Directors		
	1. Ronald H.W. Cooper	For	For
	2. Anne Klibanski, M.D.	For	For
	3. Stephanie S. Okey, M.S.	For	For
2.	To approve an amendment to Albireo's Restated Certificate of Incorporation, as amended, to increase the number of shares of common stock authorized for issuance from 30,000,000 to 60,000,000.	For	For
3.	To approve the amendment to the Albireo Pharma, Inc. 2018 Equity Incentive Plan, as amended.	For	For
4.	To ratify the appointment of Ernst & Young LLP as Albireo's independent registered public accounting firm for the fiscal year ending December 31, 2021.	For	For



## Proxy Voting Record

### MADRIGAL PHARMACEUTICALS INC.

Ticker Symbol:	MDGL	Meeting Type	Annual
CUSIP:	558868105	Meeting Date	June 8, 2021

Item	Proposal	Vote	For/Against Management
1.	Election of Directors		
	1. Rebecca Taub, M.D.	For	For
	2. Fred B. Craves, Ph.D.	For	For
2.	To approve our amended 2015 Stock Plan.	For	For
3.	To ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2021.	For	For
4.	Advisory vote on compensation of named executive officers.	For	For
5.	In their discretion, the proxies are authorized to vote and act upon any other matters which may properly come before the meeting or any adjournment or postponement thereof.	For	For

## Proxy Voting Record

### INTRA-CELLULAR THERAPIES INC

Ticker Symbol:	ITCI	Meeting Type	Annual
CUSIP:	46116X101	Meeting Date	June 21, 2021

Item	Proposal	Vote	For/Against Management
1.	Election of Directors		
	1. Sir Michael Rawlins, MD	For	For
	2. Joel S. Marcus	For	For
2.	To approve an amendment to the Company's Restated Certificate of Incorporation to increase the number of authorized shares of common stock for issuance from 100,000,000 to 175,000,000.	For	For
3.	To ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2021.	For	For
4.	To approve by an advisory vote the compensation of the Company's named executive officers, as disclosed in the proxy statement.	For	For

## Proxy Voting Record

### DECIPHERA PHARMACEUTICALS, INC.

Ticker Symbol:	DCPH	Meeting Type	Annual
CUSIP:	24344T101	Meeting Date	June 23, 2021

Item	Proposal	Vote	For/Against Management
1.	Election of Directors		
	1. James A. Bristol, Ph.D.	For	For
	2. Frank S. Friedman	For	For
	3. Ron Squarer	For	For
2.	To approve, on a non-binding, advisory basis, the compensation of our named executive officers, as disclosed in the proxy statement accompanying this notice.	For	For
3.	To recommend, on a non-binding, advisory basis, the preferred frequency of future advisory votes on compensation of our named executive officers.	For	For
4.	To ratify the appointment of PricewaterhouseCoopers LLP as Deciphera Pharmaceuticals, Inc.'s independent registered public accounting firm for the year ending December 31, 2021.	For	For

# Proxy Voting Record

## OPKO HEALTH, INC.

Ticker Symbol:	OPK	Meeting Type	Annual
CUSIP:	68375N103	Meeting Date	June 24, 2021

Item	Proposal	Vote	For/Against Management
1.	Election of Directors		
	1. Phillip Frost, M.D.	For	For
	2. Jane H. Hsiao, PhD, MBA	For	For
	3. Steven D. Rubin	For	For
	4. Jon R. Cohen, M.D.	For	For
	5. Robert S. Fishel, M.D.	For	For
	6. Richard M. Krasno, Ph.D	For	For
	7. Prem A. Lachman, M.D.	For	For
	8. Richard A. Lerner, M.D.	For	For
	9. Roger J. Medel, M.D.	For	For
	10. John A. Paganelli	For	For
	11. Richard C Pfenniger, Jr	For	For
	12. A. Lin-Tsing Yu, MD PhD	For	For
2.	A non-binding advisory vote to approve the compensation paid to named executive officers of the Company ("Say on Pay").	For	For
3.	To ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2021.	For	For

## Proxy Voting Record

### QUANTERIX CORPORATION

Ticker Symbol:	QTRX	Meeting Type	Annual
CUSIP:	74766Q101	Meeting Date	June 24, 2021

Item	Proposal	Vote	For/Against Management
1.	Election of Directors		
	1. Martin D. Madaus, PhD	For	For
	2. Laurie J. Olson	For	For
2.	Ratification of the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2021.	For	For

## Proxy Voting Record

### INHIBIKASE THERAPEUTICS, INC.

Ticker Symbol:	IKT	Meeting Type	Annual
CUSIP:	45719W106	Meeting Date	June 25, 2021

Item	Proposal	Vote	For/Against Management
1.	Election of Directors		
	1. Milton H. Werner Ph.D.	For	For
2.	To ratify the appointment of CohnReznick LLP as the Company's registered independent public accounting firm for the year ending December 31, 2021.	For	For

## Proxy Voting Record

### ERYTECH PHARMA

Ticker Symbol:	ERYP	Meeting Type	Annual
CUSIP:	29604W108	Meeting Date	June 25, 2021

Item	Proposal	Vote	For/Against Management
1.	APPROVAL OF THE FINANCIAL STATEMENTS FOR THE YEAR ENDED DECEMBER 31, 2020.	For	For
2.	APPROVAL OF THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED DECEMBER 31, 2020.	For	For
3.	ALLOCATION OF RESULTS FOR THE YEAR.	For	For
4.	APPROVAL OF THE SPECIAL REPORT OF THE STATUTORY AUDITORS ON REGULATED AGREEMENTS AND COMMITMENTS.	For	For
5.	APPROVAL OF THE INFORMATION MENTIONED IN ARTICLE L.22- 10-9 I OF THE FRENCH COMMERCIAL CODE CONCERNING THE EXECUTIVE CORPORATE OFFICERS' COMPENSATION FOR THE YEAR ENDED DECEMBER 31, 2020.	For	For
6.	APPROVAL OF THE ELEMENTS OF TOTAL COMPENSATION AND BENEFITS OF ALL KIND PAID OR ALLOCATED FOR THE YEAR ENDED DECEMBER 31, 2020 TO MR. GIL BEYEN, CHIEF EXECUTIVE OFFICER.	For	For
7.	APPROVAL OF THE ELEMENTS OF TOTAL COMPENSATION AND BENEFITS OF ALL KIND PAID OR ALLOCATED FOR THE YEAR ENDED DECEMBER 31, 2020 TO MR. JEAN-PAUL KRESS, CHAIRMAN OF THE BOARD.	For	For
8.	APPROVAL OF THE COMPENSATION POLICY FOR EXECUTIVE CORPORATE OFFICERS.	For	For

## Proxy Voting Record

9.	APPROVAL OF THE COMPENSATION POLICY FOR BOARD MEMBERS.	For	For
10.	APPROVAL OF THE REGULATIONS OF THE SHARE SUBSCRIPTION AND/OR PURCHASE OPTIONS PLAN ADOPTED BY THE BOARD OF DIRECTORS ON JULY 28, 2020.	For	For
11.	AUTHORIZATION FOR THE COMPANY TO BUY BACK ITS OWN SHARES.	For	For
12.	AUTHORIZATION FOR THE BOARD OF DIRECTORS TO REDUCE THE COMPANY'S SHARE CAPITAL BY CANCELING THE TREASURY SHARES HELD BY THE COMPANY.	For	For
13.	DELEGATION OF AUTHORITY TO THE BOARD OF DIRECTORS TO ISSUE COMMON SHARES OF THE COMPANY AND/OR SECURITIES CONVERTIBLE TO COMMON SHARES TO BE ISSUED IMMEDIATELY OR IN THE FUTURE BY THE COMPANY, WITH EXISTING SHAREHOLDERS' PREFERENTIAL SUBSCRIPTION RIGHTS MAINTAINED.	For	For
14.	DELEGATION OF AUTHORITY TO THE BOARD OF DIRECTORS TO ISSUE COMMON SHARES OF THE COMPANY AND/OR SECURITIES CONVERTIBLE TO COMMON SHARES TO BE ISSUED IMMEDIATELY OR IN THE FUTURE BY THE COMPANY, WITH SHAREHOLDERS' PREFERENTIAL SUBSCRIPTION RIGHTS WAIVED BY PUBLIC OFFERING OTHER THAN THE PUBLIC OFFERINGS REFERRED TO IN SECTION 1° OF ARTICLE L.411-2 OF THE FRENCH MONETARY AND FINANCIAL CODE.e	For	For
15.	DELEGATION OF AUTHORITY TO THE BOARD OF DIRECTORS TO ISSUE COMMON SHARES OF THE COMPANY AND/OR SECURITIES CONVERTIBLE TO COMMON SHARES TO BE ISSUED BY THE COMPANY IMMEDIATELY OR IN	For	For



## Proxy Voting Record

	THE FUTURE, WITH PREFERENTIAL SUBSCRIPTION RIGHTS WAIVED, BY PUBLIC OFFERING REFERRED TO IN SECTION 1° OF ARTICLE L.411-2 OF THE FRENCH MONETARY AND FINANCIAL CODE.		
16.	AUTHORIZATION TO THE BOARD OF DIRECTORS, IN THE CASE OF AN ISSUE, WITH EXISTING SHAREHOLDERS' PREFERENTIAL SUBSCRIPTION RIGHTS WAIVED BY PUBLIC OFFERING, OF COMMON SHARES OF THE COMPANY AND/OR SECURITIES CONVERTIBLE TO COMMON SHARES TO BE ISSUED BY THE COMPANY, TO SET THE ISSUE PRICE IN ACCORDANCE WITH THE TERMS AND CONDITIONS SET BY THE GENERAL MEETING, OF UP TO 10% OF THE SHARE CAPITAL PER YEAR.	For	For
17.	AUTHORIZATION FOR THE BOARD OF DIRECTORS, IN THE CASE OF A CAPITAL INCREASE WITH EXISTING SHAREHOLDERS' PREFERENTIAL SUBSCRIPTION RIGHTS MAINTAINED OR WAIVED, TO INCREASE THE NUMBER OF SHARES TO BE ISSUED.	For	For
18.	DELEGATION OF AUTHORITY TO THE BOARD OF DIRECTORS, WITH SHAREHOLDERS' PREFERENTIAL SUBSCRIPTION RIGHTS WAIVED, TO INCREASE THE COMPANY'S SHARE CAPITAL THROUGH AN ISSUE RESERVED FOR CERTAIN CATEGORIES OF INVESTORS.	For	For
19.	DELEGATION OF AUTHORITY TO THE BOARD OF DIRECTORS TO ISSUE COMMON SHARES OF THE COMPANY AND/OR SECURITIES CONVERTIBLE TO COMMON SHARES TO BE ISSUED BY THE COMPANY IN THE EVENT OF A PUBLIC EXCHANGE OFFER INITIATED BY THE COMPANY, WITH SHAREHOLDERS' PREFERENTIAL SUBSCRIPTION RIGHTS WAIVED.	For	For

## Proxy Voting Record

20.	AUTHORIZATION FOR THE BOARD OF DIRECTORS TO ISSUE, WITH EXISTING SHAREHOLDERS' PREFERENTIAL SUBSCRIPTION RIGHTS WAIVED, COMMON SHARES AND/OR SECURITIES CONVERTIBLE TO COMMON SHARES TO BE ISSUED, TO BE USED AS PAYMENT FOR IN-KIND CONTRIBUTIONS TO THE COMPANY CONSISTING OF EQUITY SECURITIES OR OTHER SECURITIES CONVERTIBLE TO SHARES.	For	For
21.	DELEGATION OF AUTHORITY TO THE BOARD OF DIRECTORS TO INCREASE THE COMPANY'S CAPITAL BY INCORPORATING RESERVES, PROFITS OR PREMIUMS.	For	For
22.	DELEGATION OF AUTHORITY TO THE BOARD OF DIRECTORS TO CARRY OUT CAPITAL INCREASES RESERVED FOR EMPLOYEES PARTICIPATING IN AN ERYTECH PHARMA GROUP SAVINGS PLAN, WITH SHAREHOLDERS' PREFERENTIAL SUBSCRIPTION RIGHTS WAIVED.	For	For
23.	AUTHORIZATION FOR THE BOARD OF DIRECTORS TO AWARD BONUS SHARES, EXISTING OR TO BE ISSUED, WITH EXISTING SHAREHOLDERS' PREFERENTIAL SUBSCRIPTION RIGHTS WAIVED, TO CORPORATE OFFICERS OR EMPLOYEES OF THE COMPANY OR RELATED COMPANIES.	For	For
24.	AUTHORIZATION FOR THE BOARD OF DIRECTORS TO GRANT SHARE SUBSCRIPTION AND/OR SHARE PURCHASE OPTIONS TO CORPORATE OFFICERS AND EMPLOYEES OF THE COMPANY OR COMPANIES IN THE ERYTECH PHARMA GROUP, ENTAILING THE WAIVER BY SHAREHOLDERS OF THEIR PREFERENTIAL RIGHTS TO SUBSCRIBE FOR SHARES ISSUED	For	For

## Proxy Voting Record

### FOLLOWING THE EXERCISE OF STOCK OPTIONS.

25.	AUTHORIZATION FOR THE BOARD OF DIRECTORS TO ISSUE SHARE SUBSCRIPTION WARRANTS, WITH EXISTING SHAREHOLDERS' PREFERENTIAL SUBSCRIPTION RIGHTS WAIVED, TO CORPORATE OFFICERS OR EMPLOYEES OF THE COMPANY OR ERYTECH PHARMA GROUP COMPANIES.	For	For
26.	HARMONIZATION OF THE BY-LAWS WITH THE LAW AND REGULATIONS IN FORCE.	For	For
27.	POWERS FOR CARRYING OUT FORMALITIES.	For	For

## Proxy Voting Record

### CARDIOL THERAPEUTICS INC.

Ticker Symbol:	CRTPF	Meeting Type	Annual and Special Meeting
CUSIP:	14161Y200	Meeting Date	June 29, 2021

Item	Proposal	Vote	For/Against Management
1.	Election of Directors		
	1. David Elsley	For	For
	2. Dr. Eldon R. Smith	For	For
	3. Deborah Brown	For	For
	4. Iain Chalmers	For	For
	5. Colin Stott	For	For
	6. Peter Pekos	For	For
	7. Dr. G. Torre-Amione	For	For
2.	To appoint BDO Canada LLP, Chartered Professional Accountants, as auditors of the Corporation and to authorize remuneration to be fixed by the Board.	For	For
3.	To consider and, if thought fit, to pass, with or without variation, an ordinary resolution to approve the Corporation's Omnibus Equity Incentive Plan, as more particularly described in the accompanying management information circular.	For	For

## Proxy Voting Record

### PROMIS NEUROSCIENCES INC.

Ticker Symbol:	ARFXF	Meeting Type	Annual
CUSIP:	74346M109	Meeting Date	June 30, 2021

Item	Proposal	Vote	For/Against Management
1.	Election of Directors		
	1. Eugene Williams	For	For
	2. Neil Cashman	For	For
	3. William Wyman	For	For
	4. Richard J. Gregory	For	For
	5. Patrick D. Kirwin	For	For
	6. Neil K. Warma	For	For
2.	To appoint PricewaterhouseCoopers LLP as Auditor of the Corporation for the ensuing year and to authorize the Directors to fix the Auditor's remuneration.	For	For
3.	To approve the ordinary resolution by disinterested shareholder vote, to approve and authorize the unallocated Options issuable pursuant to the Stock Option Plan of the Corporation, as amended from time to time, until June 30, 2024, as more particularly described in the Corporation's Management Proxy Circular.	For	For